Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
FDA grants breakthrough device designation to Elecsys GALAD score to support liver cancer diagnosis
The FDA granted breakthrough device designation to the Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma.
Cedars-Sinai receives $9.1 million for liver cancer research
The National Cancer Institute awarded a Cedars-Sinai team $9.1 million by to study how cancer metastasizes to the liver and finding ways to block it. Consisting of four parts, the study’s main focus will be the interaction between dietary fat and fatty liver disease as well as the mechanisms that allow for the spread, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma
Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.
FDA grants orphan drug designation to durvalumab-tremelimumab combination for liver cancer
The FDA granted orphan drug designation to durvalumab and tremelimumab for treatment of patients with advanced hepatocellular carcinoma.
Combination therapy trial for locally advanced, metastatic HCC underway
CStone Pharmaceuticals and Blueprint Medicines Corporation announced the first patient dosed in a phase 1b/2 trial of fisobatinib in combination with CS1001 for the treatment of locally advanced or metastatic hepatocellular carcinoma, according to a press release.
Modified PAGE-B score classifies HCC risk in patients undergoing HBV therapy
The PAGE-B score and a modified PAGE-B score identified which patients on antiviral therapy for chronic hepatitis B had a low risk for hepatocellular carcinoma development, according to published data.
Diets high in polyunsaturated, vegetable fats reduce liver cancer risk
Diets consisting of higher vegetable fat and polyunsaturated fat intake correlated with a lower risk for hepatocellular carcinoma, including cases in which individuals replaced other animal, dairy, or saturated fats with vegetable and polyunsaturated fats, according to data.
ACG issues new guideline on hepatic, mesenteric circulation disorders
The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries, which can lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.
Infections caused 13% of cancers in 2018
In 2018, infections were the cause of 13% of all new cancer diagnoses, totaling 2.2 million new cases worldwide, although these totals do not include nonmelanoma skin cancers, according to findings published in The Lancet Global Health.
MRI finds more cases of liver cancer than ultrasonography in less time
Nonenhanced MRI showed promise as an option for hepatocellular carcinoma surveillance in high-risk patients based on high-performance results with a short scan time and lack of contrast agent-associated risks, according to a study published in Journal of Hepatology.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read